Literature DB >> 18718648

Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations.

Aasia Saleemuddin1, Ann K Folkins, Leslie Garrett, Judy Garber, Michael G Muto, Christopher P Crum, Shelley Tworoger.   

Abstract

OBJECTIVES: Pelvic (ovarian) serous carcinomas frequently contain p53 mutations. Recently, a candidate serous cancer precursor (the p53 signature) with p53 mutations and other features in common with serous cancer has been discovered in distal fallopian tube mucosa. This study examined the relationship of putative ovarian cancer risk factors with the presence of p53 signatures in women with BRCA mutations (BRCA+).
METHODS: Fallopian tubes from 75 BRCA+ women were immunostained for p53 signatures and correlated with age at first childbirth, parity, oral contraceptive use, body mass index (BMI), and BRCA subtype (1 or 2). Statistical analysis was performed with the T-test or Chi-square analysis and logistic regression adjusting for age and parity.
RESULTS: Thirty-eight percent of the tubes contained p53 signatures, which were significantly associated with older age at first childbirth (mean 30.8 vs. 28.4 years; p=0.04) and lower parity (mean 1.4 vs. 2.2; p=0.01) in univariate analyses. The unadjusted odds ratios were 3.8 (p-trend=0.04) for first childbirth>/=30 years versus <30 and 0.2 (p-trend=0.01) for parity >/= 3 versus nulliparous women. After adjusting for age and parity, the trend for age at first childbirth became non-significant (adjusted odds ratio 3.5; p-trend=0.15), while that for parity remained significant (adjusted odds ratio 0.2; p-trend 0.02).
CONCLUSIONS: The p53 signature is significantly associated with lower parity and possibly higher age at first childbirth, further linking this entity to serous cancer via risk factors associated with ovulation. The p53 signature merits consideration as a surrogate marker for serous cancer risk.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18718648      PMCID: PMC2613977          DOI: 10.1016/j.ygyno.2008.07.018

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  37 in total

1.  Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes.

Authors:  R R Barakat; M G Federici; P E Saigo; M E Robson; K Offit; J Boyd
Journal:  Cancer       Date:  2000-07-15       Impact factor: 6.860

2.  Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

Authors:  David W Kindelberger; Yonghee Lee; Alexander Miron; Michelle S Hirsch; Colleen Feltmate; Fabiola Medeiros; Michael J Callahan; Elizabeth O Garner; Robert W Gordon; Chandler Birch; Ross S Berkowitz; Michael G Muto; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

3.  Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.

Authors:  B Modan; P Hartge; G Hirsh-Yechezkel; A Chetrit; F Lubin; U Beller; G Ben-Baruch; A Fishman; J Menczer; J P Struewing; M A Tucker; S Wacholder
Journal:  N Engl J Med       Date:  2001-07-26       Impact factor: 91.245

4.  Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.

Authors:  John R McLaughlin; Harvey A Risch; Jan Lubinski; Pal Moller; Parviz Ghadirian; Henry Lynch; Beth Karlan; David Fishman; Barry Rosen; Susan L Neuhausen; Kenneth Offit; Noah Kauff; Susan Domchek; Nadine Tung; Eitan Friedman; William Foulkes; Ping Sun; Steven A Narod
Journal:  Lancet Oncol       Date:  2007-01       Impact factor: 41.316

5.  Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.

Authors:  S A Narod; P Sun; P Ghadirian; H Lynch; C Isaacs; J Garber; B Weber; B Karlan; D Fishman; B Rosen; N Tung; S L Neuhausen
Journal:  Lancet       Date:  2001-05-12       Impact factor: 79.321

6.  Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.

Authors:  Johnathan M Lancaster; C Bethan Powell; Noah D Kauff; Ilana Cass; Lee-May Chen; Karen H Lu; David G Mutch; Andrew Berchuck; Beth Y Karlan; Thomas J Herzog
Journal:  Gynecol Oncol       Date:  2007-11       Impact factor: 5.482

7.  A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.

Authors:  Ann K Folkins; Elke A Jarboe; Aasia Saleemuddin; Yonghee Lee; Michael J Callahan; Ronny Drapkin; Judy E Garber; Michael G Muto; Shelley Tworoger; Christopher P Crum
Journal:  Gynecol Oncol       Date:  2008-03-14       Impact factor: 5.482

Review 8.  Updating on primary fallopian tube carcinoma.

Authors:  Annika Riska; Arto Leminen
Journal:  Acta Obstet Gynecol Scand       Date:  2007       Impact factor: 3.636

9.  Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk.

Authors:  Shelley S Tworoger; Kathleen M Fairfield; Graham A Colditz; Bernard A Rosner; Susan E Hankinson
Journal:  Am J Epidemiol       Date:  2007-07-26       Impact factor: 4.897

10.  Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.

Authors:  Joseph W Carlson; Alexander Miron; Elke A Jarboe; Mana M Parast; Michelle S Hirsch; Yonghee Lee; Michael G Muto; David Kindelberger; Christopher P Crum
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

View more
  27 in total

1.  The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube.

Authors:  Wa Xian; Alexander Miron; Michael Roh; Dana R Semmel; Yosuf Yassin; Judy Garber; Esther Oliva; Annekathryn Goodman; Karishma Mehra; Ross S Berkowitz; Christopher P Crum; Bradley J Quade
Journal:  J Pathol       Date:  2010-01       Impact factor: 7.996

2.  Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.

Authors:  Melinda S Yates; Larissa A Meyer; Michael T Deavers; Molly S Daniels; Elizabeth R Keeler; Samuel C Mok; David M Gershenson; Karen H Lu
Journal:  Cancer Prev Res (Phila)       Date:  2011-01-28

3.  Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube.

Authors:  Eleanor Y Chen; Karishma Mehra; Mitra Mehrad; Gang Ning; Alexander Miron; George L Mutter; Nicholas Monte; Bradley J Quade; Frank D McKeon; Yosuf Yassin; Wa Xian; Christopher P Crum
Journal:  J Pathol       Date:  2010-09       Impact factor: 7.996

4.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

5.  The detection, treatment, and biology of epithelial ovarian cancer.

Authors:  Jennifer Aa Gubbels; Nick Claussen; Arvinder K Kapur; Joseph P Connor; Manish S Patankar
Journal:  J Ovarian Res       Date:  2010-03-29       Impact factor: 4.234

6.  Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma.

Authors:  Benjamin Piura; Ettie Piura
Journal:  J Oncol       Date:  2010-01-17       Impact factor: 4.375

7.  Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics.

Authors:  Amy L Gross; Robert J Kurman; Russell Vang; Ie-Ming Shih; Kala Visvanathan
Journal:  J Oncol       Date:  2010-04-27       Impact factor: 4.375

8.  Ovarian cancer pathogenesis: a model in evolution.

Authors:  Alison M Karst; Ronny Drapkin
Journal:  J Oncol       Date:  2009-09-06       Impact factor: 4.375

Review 9.  Intercepting pelvic cancer in the distal fallopian tube: theories and realities.

Authors:  Christopher P Crum
Journal:  Mol Oncol       Date:  2009-02-03       Impact factor: 6.603

10.  Epidemiologic correlates of ovarian cortical inclusion cysts (CICs) support a dual precursor pathway to pelvic epithelial cancer.

Authors:  Ann K Folkins; Aasia Saleemuddin; Leslie A Garrett; Judy E Garber; Michael G Muto; Shelley S Tworoger; Christopher P Crum
Journal:  Gynecol Oncol       Date:  2009-07-16       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.